JP2013508400A - 新規な投与レジメンおよび治療法 - Google Patents

新規な投与レジメンおよび治療法 Download PDF

Info

Publication number
JP2013508400A
JP2013508400A JP2012535373A JP2012535373A JP2013508400A JP 2013508400 A JP2013508400 A JP 2013508400A JP 2012535373 A JP2012535373 A JP 2012535373A JP 2012535373 A JP2012535373 A JP 2012535373A JP 2013508400 A JP2013508400 A JP 2013508400A
Authority
JP
Japan
Prior art keywords
weeks
days
administered
cancer
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012535373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508400A5 (enExample
Inventor
ランバート，ジョン
オリーリ，ジェームズ，ジェイ
シンドラー，ジョアン，エリザベス，サラ
ウェイトマン，スティーブン
チン，アルバート
Original Assignee
イミュノジェン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノジェン・インコーポレーテッド filed Critical イミュノジェン・インコーポレーテッド
Publication of JP2013508400A publication Critical patent/JP2013508400A/ja
Publication of JP2013508400A5 publication Critical patent/JP2013508400A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012535373A 2009-10-21 2010-10-21 新規な投与レジメンおよび治療法 Withdrawn JP2013508400A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25380409P 2009-10-21 2009-10-21
US61/253,804 2009-10-21
PCT/US2010/053579 WO2011050180A1 (en) 2009-10-21 2010-10-21 Novel dosing regimen and method of treatment

Publications (2)

Publication Number Publication Date
JP2013508400A true JP2013508400A (ja) 2013-03-07
JP2013508400A5 JP2013508400A5 (enExample) 2013-12-05

Family

ID=43898626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535373A Withdrawn JP2013508400A (ja) 2009-10-21 2010-10-21 新規な投与レジメンおよび治療法

Country Status (13)

Country Link
US (1) US20110097345A1 (enExample)
EP (1) EP2490715A4 (enExample)
JP (1) JP2013508400A (enExample)
KR (1) KR20120094472A (enExample)
CN (1) CN102630165A (enExample)
AU (1) AU2010310577A1 (enExample)
BR (1) BR112012009250A2 (enExample)
CA (1) CA2775806A1 (enExample)
IL (1) IL219279A0 (enExample)
IN (1) IN2012DN02826A (enExample)
MX (1) MX2012004406A (enExample)
RU (1) RU2012120691A (enExample)
WO (1) WO2011050180A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520082A (ja) * 2013-05-14 2016-07-11 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体投与計画
JP2016534039A (ja) * 2013-10-08 2016-11-04 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2017502048A (ja) * 2014-01-08 2017-01-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
JP2019526546A (ja) * 2016-08-10 2019-09-19 セルジーン コーポレーションＣｅｌｇｅｎｅ Ｃｏｒｐｏｒａｔｉｏｎ 再発性および／または難治性の固形腫瘍および非ホジキンリンパ腫の処置
JP2021528471A (ja) * 2018-06-26 2021-10-21 イミュノジェン・インコーポレーテッド Ａｄａｍ９を標的とする免疫コンジュゲート、及び、その使用の方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
MX2012008383A (es) * 2010-01-21 2012-11-23 Immunogen Inc Composiciones y metodos para el tratamiento de cancer de ovario.
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014052876A1 (en) * 2012-09-28 2014-04-03 Immunogen Inc. Methods for increasing efficacy of cd56- based therapy
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US20230322933A1 (en) * 2020-06-04 2023-10-12 Bioinvent International Ab Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN121152872A (zh) * 2023-05-10 2025-12-16 南京传奇生物科技有限公司 嵌合抗原受体及其使用方法
WO2026117599A2 (en) * 2024-11-26 2026-06-04 Immunome, Inc. Immunoconjugates for ncam1 and methods of use
CN120053673B (zh) * 2025-02-11 2026-05-05 暨南大学 纳米前药及其制备方法和用途
CN120173115A (zh) * 2025-05-20 2025-06-20 苏州欣协生物科技有限公司 一种抗人cd56蛋白工程抗体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP4776843B2 (ja) * 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
IL159422A0 (en) * 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
KR20060080535A (ko) * 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
EP1628631A2 (en) * 2003-06-05 2006-03-01 Achkar, Charles C. Methods of treating hyperproliferative cell disorders
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
PL2081595T3 (pl) * 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
KR20110028450A (ko) * 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
MX2012008383A (es) * 2010-01-21 2012-11-23 Immunogen Inc Composiciones y metodos para el tratamiento de cancer de ovario.
AU2012240448A1 (en) * 2011-04-01 2013-03-28 Immunogen, Inc. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520082A (ja) * 2013-05-14 2016-07-11 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体投与計画
JP2023162436A (ja) * 2013-05-14 2023-11-08 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体投与計画
JP2016534039A (ja) * 2013-10-08 2016-11-04 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP7386208B2 (ja) 2013-10-08 2023-11-24 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2019031568A (ja) * 2013-10-08 2019-02-28 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2021178847A (ja) * 2013-10-08 2021-11-18 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
JP2019196383A (ja) * 2014-01-08 2019-11-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
JP7316862B2 (ja) 2014-01-08 2023-07-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
JP2017502048A (ja) * 2014-01-08 2017-01-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
JP7716299B2 (ja) 2014-01-08 2025-07-31 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
JP6998938B2 (ja) 2016-08-10 2022-02-04 セルジーン クオンティセル リサーチ，インク． 再発性および／または難治性の固形腫瘍および非ホジキンリンパ腫の処置
JP2019526546A (ja) * 2016-08-10 2019-09-19 セルジーン コーポレーションＣｅｌｇｅｎｅ Ｃｏｒｐｏｒａｔｉｏｎ 再発性および／または難治性の固形腫瘍および非ホジキンリンパ腫の処置
JP2021528471A (ja) * 2018-06-26 2021-10-21 イミュノジェン・インコーポレーテッド Ａｄａｍ９を標的とする免疫コンジュゲート、及び、その使用の方法

Also Published As

Publication number Publication date
CN102630165A (zh) 2012-08-08
CA2775806A1 (en) 2011-04-28
IN2012DN02826A (enExample) 2015-07-24
US20110097345A1 (en) 2011-04-28
BR112012009250A2 (pt) 2017-06-20
WO2011050180A1 (en) 2011-04-28
MX2012004406A (es) 2012-05-08
EP2490715A4 (en) 2013-06-26
KR20120094472A (ko) 2012-08-24
RU2012120691A (ru) 2013-11-27
EP2490715A1 (en) 2012-08-29
IL219279A0 (en) 2012-06-28
AU2010310577A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
US20110097345A1 (en) Novel dosing regimen and method of treatment
Trail et al. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design
US20230110128A1 (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
CN101287498B (zh) Psma抗体-药物缀合物
EP1626740B1 (en) Drug conjugate composition
US9242012B2 (en) Methods for killing PSMA-expressing, taxane-resistant cancer cells
JP7337824B2 (ja) 抗ｃｄ３３および抗ｃｄ７併用療法
US20250339551A1 (en) An antibody-drug conjugate having two or more different functional small molecules for enhanced treatment of refractory diseases
JP2007500236A (ja) 組換え抗ｃｄ３０抗体とその使用
TW201900221A (zh) 抗folr1免疫偶聯物與抗pd-1抗體之組合
JP2021525735A (ja) 抗ｃｄ３７免疫コンジュゲート投薬レジメン
JPH07316074A (ja) 腫瘍および炎症性疾患を選択的に治療するために用いられる、壊死を引き起こす物質と、壊死により活性化される物質との組み合わせ
CA2858133A1 (en) Uses of immunoconjugates targeting cd138
KR20120104491A (ko) 암 치료를 위한 실렌기티드의 연속 투여
KR20250154496A (ko) Ceacam5를 발현하는 신경내분비암을 치료하기 위한 항-ceacam5 면역접합체의 용도
CN116490213A (zh) 用于治疗癌症的人源化抗liv1抗体
Tumey Next generation payloads for ADCs
AU5663796A (en) Methods of inducing immune tolerance using immunotoxins
TW202513094A (zh) 含有抗ceacam5抗體藥物接合物、抗pd1/pd-l1抗體及抗ctla4抗體之抗腫瘤組合
US20240254238A1 (en) Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
JP2025519980A (ja) Ｐｄ－１阻害剤またはｐｄ－ｌ１阻害剤およびクローディン１８．２を標的にする抗体－薬物コンジュゲートによるがん処置
JP2023543026A (ja) がんの処置のためのヒト化抗ｌｉｖ１抗体
HK1174551A (en) Novel dosing regimen and method of treatment
EP3230322A1 (en) Bi-functional allosteric protein-drug molecules for targeted therapy
JP2022522011A (ja) 骨肉腫を治療するための組成物及び使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131021

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140722